Geron (NASDAQ:GERN) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01, Bloomberg Earnings reports. Geron had a negative return on equity of 21.70% and a negative net margin of 5,328.80%. The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.20 million.
Geron stock traded up $0.01 during trading hours on Friday, reaching $1.16. 1,775,920 shares of the company’s stock were exchanged, compared to its average volume of 1,632,048. The firm has a market cap of $214.49 million, a price-to-earnings ratio of -7.25 and a beta of 2.60. The stock’s 50 day moving average price is $1.35. Geron has a twelve month low of $0.95 and a twelve month high of $6.99.
GERN has been the subject of a number of recent analyst reports. Needham & Company LLC upgraded Geron from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, April 9th. BidaskClub downgraded Geron from a “hold” rating to a “sell” rating in a report on Thursday, June 13th. ValuEngine upgraded Geron from a “sell” rating to a “hold” rating in a report on Thursday. Finally, B. Riley increased their price target on Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a report on Friday, June 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Geron has a consensus rating of “Hold” and an average price target of $3.33.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Further Reading: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.